Convulsions and intracranial calcifications in a leukemic infant receiving only intrathecal methotrexate as central nervous system prophylaxis.
Russo
A
A
Istituto di Clinica Pediatrica I, Università di Catania, Italy.
Di Bella
D
D
Lo Bianco
M
M
Rizzari
C
C
Schilirò
G
G
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001215:Asparaginase / Q000008:administration & dosage; D001927:Brain Diseases / Q000139:chemically induced*; D002114:Calcinosis / Q000139:chemically induced*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D007223:Infant; D007278:Injections, Spinal; D008297:Male; D008577:Meningeal Neoplasms / Q000517:prevention & control; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D012640:Seizures / Q000139:chemically induced*; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D001215:Asparaginase; D011241:Prednisone; D008727:Methotrexate